h2o Therapeutics Announces Collaboration With AmerisourceBergen to Support the Commercialization of Apple Watch-Based App Parky for Parkinson's Disease

ANKARA, Turkey & CONSHOHOCKEN, Penn., April 28, 2023 (Newswire.com) - Digital health start-up h2o Therapeutics today announced a collaboration with global healthcare company AmerisourceBergen to support the commercialization of Parky, a prescription mobile app cleared by the U.S. Food and Drug Administration (FDA) for monitoring certain symptoms in adults with Parkinson's Disease. 

The Parky app, which is compatible with the Movement Disorder API developed by Apple Inc., monitors symptoms such as tremors and dyskinesia in real time via the use of Apple Inc.'s Apple Watch. It is a direct-to-patient tool for sharing meaningful and reliable data between patients and medical professionals regarding the course of the disease. As part of a pilot arrangement, AmerisourceBergen will facilitate patient engagement and health system integration services as part of its DTx Connect solution. 

"Following the recent FDA clearance, we continue to focus on strategies and solutions that will enable us to expand patient access to Parky," said Yagmur Selin Gulmus, the founder of h2o Therapeutics. "Through this arrangement with AmerisourceBergen, our goal is to reduce barriers along the patient journey, improve access and expand our commercial reach. In support of the Parkinson's Disease community, we are proud to launch our patient-oriented technology during Parkinson's Awareness Month."

"Digital therapeutics offer tremendous potential, but developers face unique challenges that can affect market access and product potential," said Alex Kilgore, PharmD, Product Manager, Global Products and Solutions at AmerisourceBergen. "We look forward to supporting h2o Therapeutics and will leverage our digital health capabilities to help patients start on the Parky app following a prescription." 

Parkinson's Disease, the fastest-growing neurological disorder, affects more than 10 million people worldwide, including about one million people in the United States, according to the Parkinson's Foundation. The Parky App aims to help healthcare providers develop a profile of the patient in daily life, bridging the gap between real-life and in-clinic settings. 

AmerisourceBergen offers a wide range of services to support DTx developers and biopharmaceutical companies across the commercialization journey, including market access consulting, distribution and patient support services. The company in 2022 announced its plans to develop and launch DTx Connect, a cloud-based, fully integrated ordering, dispensing, and fulfillment platform that aims to facilitate patient access to physician-ordered digital therapeutics and digital diagnostics. 

"During Parkinson's Awareness Month, AmerisourceBergen could not be prouder to stand together with Parkinson's Disease patients, their families and healthcare providers, and innovative digital health technology developers like h2o Therapeutics to support the best patient care," said Jason Dinger, Senior Vice President of Global Products and Solutions at AmerisourceBergen. 

About h2o Therapeutics

h2o Therapeutics is developing digital therapeutics with a focus on wearable technologies, Augmented Reality (AR), and Artificial Intelligence (AI). h2o intends to make real-time human data become a handy tool for disease management in certain therapeutic areas. Our core understanding of digital therapeutics lies in the power of AI, the robustness of their clinical health research, and high levels of user engagement. Parky, a Parkinson's Disease prescription mobile app, received 510(k) clearance from the FDA in 2022. 

About AmerisourceBergen

AmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Our 44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500 with more than $200 billion in annual revenue. Learn more at www.amerisourcebergen.com.

Source: h2o Therapeutics